Table 1 Baseline clinical and pathological characteristics.
Characteristic (n = 458) | n (%) |
|---|---|
Sex | |
Male | 337 (73.6%) |
Female | 121 (26.4%) |
Age at nivolumab initiation (years) | |
Median (range) | 67.3 (30.4–87.9) |
ECOG PS | |
0 | 134 (31.3%) |
1 | 265 (61.9%) |
2 | 29 (6.8%) |
Unknown | 30 |
Histology | |
Clear cell carcinoma | 426 (93.2%) |
Other | 31 (6.8%) |
Unknown | 1 |
Primary tumor grade | |
G1-2 | 173 (45.2%) |
G3-4 | 210 (54.8%) |
Unknown | 75 |
IMDC risk group | |
Favorable-risk group | 124 (29.2%) |
Intermediate-risk group | 244 (57.4%) |
Poor | 57 (13.4%) |
Unknown | 33 |
Synchronous metastases | |
Yes | 172 (40.0%) |
No | 258 (60.0%) |
Unknown | 28 |
Line of systemic therapy | |
Second | 287 (62.7%) |
Third or higher | 171 (37.3%) |
Previous nephrectomy | |
Yes | 376 (82.1%) |
No | 82 (18.4%) |
Bone metastases | |
Yes | 87 (19.0%) |
No | 371 (81.0%) |
AEC at baseline | |
Median (range) | 130 (0–4300) cells/µL |
≥ 70 cells/Μl | 364 (80.0%) |
< 70 cells/Μl | 91 (20.0%) |
Unknown | 3 |
AEC one month after nivolumab initiation | |
Median (range) | 180 (0–5100) cells/µL |
≥ 70 cells/Μl | 364 (84.8%) |
< 70 cells/µL | 65 (15.2%) |
Unknown | 29 |
NER at baseline | |
Median (range) | 31.1 (1.33–1777) |
≥ 65 | 101 (22.2%) |
< 65 | 354 (77.8%) |
Unknown | 3 |
NER one month after nivolumab initiation | |
Median (range) | 27.3 (0.89–1000) |
≥ 65 | 82 (19.2%) |
< 65 | 345 (80.8%) |
Unknown | 31 |
Δ AEC | |
Median (range) | 25.0 (−98.4–6300) % |
≥−30% | 367 (86.2%) |
<−30% | 59 (13.8%) |
Unknown | 32 |
Δ NER | |
Median (range) | −7.2 (−97.3–6300) % |
< 125%≥125% | 43 (10.1%) |
< 125% | 381 (89.9%) |
Unknown | 34 |
